[Alex D.]

Good overview Jake. I’d add a note on the mechanism since it’s genuinely interesting: Semaglutide acts on GLP-1 receptors in the hypothalamus (satiety signaling) and also slows gastric emptying, both effects contribute to appetite regulation. The combination of central and peripheral mechanisms is part of why the appetite effects in research are more pronounced than with some earlier GLP-1 analogs.

The 7-day half-life also means once-weekly administration in clinical protocols, which is a convenience advantage worth noting.

[Alex D.]

Appreciate the detail here. Your protocol (250mcg subQ near target tissue) aligns with a lot of what the research literature uses. The 5-on/2-off pattern is a common cycling approach.

The gradual onset you described, minimal effect early, accumulating over weeks – is consistent with tissue remodeling timelines. Collagen and connective tissue turnover is slow by nature. 8-12 weeks is often the window where meaningful changes become noticeable.

[Alex D.]

Great question and the confusion is understandable, they’re closely related but not identical.

Fragment 176-191 refers specifically to amino acids 176-191 of the hGH sequence. AOD-9604 is a modified version of that same fragment with an added tyrosine residue at the N-terminus, which was designed to improve stability and activity.

So: Fragment 176-191 is the naturally-occurring sequence; AOD-9604 is a synthetic modification of it. In practice many people use the names interchangeably which adds to the confusion.

On the clinical history: AOD-9604 did advance through clinical trials (including Phase 2b for obesity) and received FDA GRAS (Generally Recognized As Safe) status as a food ingredient. It didn’t complete Phase 3 for the obesity indication, but the GRAS designation is notable and distinguishes it from many research peptides.

[Alex D.]

Good breakdown Pete. I’d also add: avoid high-fat meals 2+ hours before dosing if possible, dietary fat can also blunt GH response. The main thing to avoid is a large insulin spike close to dosing time.

For the CJC-1295 specifically, are you using the DAC version or without DAC? The half-life difference is significant and affects dosing frequency.

[Alex D.]

Pete covered it well. I’d add: avoid drawing up more than you need in a single syringe, each time you pierce the septum you introduce potential contamination. Use a fresh needle each time you draw.

Also label your vials with the reconstitution date so you don’t lose track.

[Author]

Posts